Biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) reported a decline in fourth-quarter earnings, despite a modest increase in revenues. Earnings fell short of expectations, while revenues beat. The company’s stock dropped soon after the announcement during Monday’s extended trading session.
Fourth-quarter adjusted earnings decreased to $1.30 per share from $1.44 per share a year earlier. Analysts were looking for a bigger bottom-line number.
Gross margin was negatively impacted by an increase in selling costs amid inventory write-downs, which was partially offset by lower royalty expenses and R&D expenses.
Net income, on an unadjusted basis, came in at $2.7 billion or $2.12 per share, compared to flat earnings in the prior-year period. The improvement primarily reflects favorable tax effects and gains from equity securities.
Revenue up
Revenues, meanwhile, edged up 1% year-over-year to $5.88 billion and exceeded the market’s prediction. At $5.8 billion, product sales were up 2%. Product sales in the U.S market were unchanged from the prior-year period, but Europe registred a model decline.
Product-wise, higher sales volumes of HIV drug Biktarvy pushed up overall sales. However, it was partially offset by a drop in the sales of chronic hepatitis C virus products.
Outlook
For fiscal 2020, the company currently forecasts product sales in the range of $21.8 billion to $22.2 billion, and unadjusted earnings between $5.15 per share and $5.55 per share. On an adjusted basis, full-year earnings are forecast to be in the $6.05-$6.45 range. The management sees research and development expenses to increase in the mid-single-digit percentage.
Gilead Sciences shares made strong gains this week and closed Tuesday’s regular session higher. The stock, which witnessed significant volatility in the past twelve months, rose 17% since the beginning of the year.
Most Popular
Important takeaways from Conagra Brands’ Q3 2025 report
Conagra Brands, Inc. (NYSE: CAG) has reported weaker-than-expected revenue and profit for the February quarter, with sales declining across all business segments amid softer demand and persistent supply challenges. The
Main takeaways from Lamb Weston’s (LW) Q3 2025 earnings report
Shares of Lamb Weston Holdings, Inc. (NYSE: LW) jumped 9% on Thursday after the company delivered better-than-expected results for the third quarter of 2025 and reaffirmed its outlook for the
Summary: Tesla (TSLA) reports Q1 2025 production, deliveries
Tesla Inc. (NASDAQ: TSLA) has announced results of vehicle production and deliveries for the first quarter of 2025. The company also provided data on the deployment of energy storage products
